Wei L, Xu C, Gao L, Chen D, Duan Y, Gao X
Transl Cancer Res. 2022; 11(8):2733-2741.
PMID: 36093557
PMC: 9459650.
DOI: 10.21037/tcr-22-308.
Ino A, Sakanaka K, Inoo H, Ishida Y, Kanda J, Mizowaki T
Int Cancer Conf J. 2021; 10(3):201-206.
PMID: 34221832
PMC: 8206320.
DOI: 10.1007/s13691-021-00479-x.
DeCesaris C, Berger M, Choi J, Carr S, Burrows W, Regine W
J Gastrointest Oncol. 2020; 11(4):663-673.
PMID: 32953150
PMC: 7475327.
DOI: 10.21037/jgo-20-205.
van der Wilk B, Eyck B, Lagarde S, van der Gaast A, Nuyttens J, Wijnhoven B
J Thorac Dis. 2019; 11(Suppl 5):S621-S631.
PMID: 31080638
PMC: 6503275.
DOI: 10.21037/jtd.2018.11.143.
van der Wilk B, Eyck B, Spaander M, Valkema R, Lagarde S, Wijnhoven B
Dig Surg. 2018; 36(6):462-469.
PMID: 30227434
PMC: 6878756.
DOI: 10.1159/000493435.
Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older.
Huang S, Zheng S, Gong T, Ma H, Ke Y, Zhao S
Oncotarget. 2018; 8(67):112094-112102.
PMID: 29340114
PMC: 5762382.
DOI: 10.18632/oncotarget.22884.
High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma.
Oh D, Noh J, Nam H, Lee H, Kim T, Ahn Y
Medicine (Baltimore). 2016; 95(33):e4591.
PMID: 27537591
PMC: 5370817.
DOI: 10.1097/MD.0000000000004591.
Radiotherapy of 180 cases of operable esophageal carcinoma.
Chen D, Yang Z, Yin W
World J Gastroenterol. 2016; 3(2):123-6.
PMID: 27041971
PMC: 4801919.
DOI: 10.3748/wjg.v3.i2.123.
Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer.
Fulton B, Gray J, McDonald A, McIntosh D, MacLaren V, Hennessy A
J Gastrointest Oncol. 2016; 7(2):166-72.
PMID: 27034782
PMC: 4783746.
DOI: 10.3978/j.issn.2078-6891.2015.068.
The role of induction therapy.
Moremen J, Skopelja E, Ceppa D
J Thorac Dis. 2014; 6 Suppl 3:S309-13.
PMID: 24876935
PMC: 4037412.
DOI: 10.3978/j.issn.2072-1439.2014.03.10.
Role of barium esophagography in patients with locally advanced esophageal cancer: evaluation of response to neoadjuvant chemoradiotherapy.
Tsurumaru D, Hiraka K, Komori M, Shioyama Y, Morita M, Honda H
Radiol Res Pract. 2013; 2013:502690.
PMID: 24369500
PMC: 3867826.
DOI: 10.1155/2013/502690.
Curative treatment of esophageal cancer; an evidenced based review.
Shridhar R, Imani-Shikhabadi R, Davis B, Streeter O, Thomas Jr C
J Gastrointest Cancer. 2013; 44(4):375-84.
PMID: 23824628
DOI: 10.1007/s12029-013-9511-9.
Gender differences in prognosis after esophagectomy for esophageal cancer.
Morita M, Otsu H, Kawano H, Kasagi Y, Kimura Y, Saeki H
Surg Today. 2013; 44(3):505-12.
PMID: 23563736
DOI: 10.1007/s00595-013-0573-x.
Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.
Chiba I, Ogawa K, Morioka T, Shimoji H, Sunagawa N, Iraha S
Oncol Lett. 2012; 2(1):21-28.
PMID: 22870123
PMC: 3412522.
DOI: 10.3892/ol.2010.199.
Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M
Oncol Rep. 2012; 28(2):446-52.
PMID: 22664791
PMC: 3583592.
DOI: 10.3892/or.2012.1847.
Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51.
Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C
PLoS One. 2011; 6(8):e23427.
PMID: 21858113
PMC: 3152570.
DOI: 10.1371/journal.pone.0023427.
Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy.
Morita M, Kumashiro R, Hisamatsu Y, Nakanishi R, Egashira A, Saeki H
J Gastroenterol. 2011; 46(11):1284-91.
PMID: 21818602
DOI: 10.1007/s00535-011-0448-0.
Neoadjuvant treatment of esophageal cancer.
Campbell N, Villaflor V
World J Gastroenterol. 2010; 16(30):3793-803.
PMID: 20698042
PMC: 2921091.
DOI: 10.3748/wjg.v16.i30.3793.
Chemoradiotherapy for esophageal cancer.
Neuner G, Patel A, Suntharalingam M
Gastrointest Cancer Res. 2009; 3(2):57-65.
PMID: 19461907
PMC: 2684724.
Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus.
Westerterp M, Boermeester M, Omloo J, Hulshof M, Vervenne W, Lutter R
Cancer Immunol Immunother. 2008; 57(12):1837-47.
PMID: 18398607
PMC: 11030738.
DOI: 10.1007/s00262-008-0511-8.